UPDATE: Cowen Starts Foamix Pharmaceuticals (FOMX) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St futures subdued as investors weigh earnings, oil prices
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil prices hit fresh 6-week highs on renewed Middle East tensions
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
Barclays Starts Foamix Pharmaceuticals (FOMX) at Overweight
October 13, 2014 6:43 AM EDTBarclays initiated coverage on Foamix Pharmaceuticals (NASDAQ: FOMX) with an Overweight rating and a price target of $11.00.
For an analyst ratings summary and ratings history on Foamix Pharmaceuticals click here. For more ratings news on Foamix Pharmaceuticals click here.
Shares of Foamix Pharmaceuticals closed at $5.08 yesterday.
... More